HIV
Colombia seeks to slash HIV drug costs by overriding ViiVās patent
Colombia has taken a significant step in response to a pricing dispute with GSK’s ViiV Healthcare regarding the HIV medication ...
GSK aims to boost HIV sales to Ā£7B with new drugs and launches
GSK is charting an optimistic course for its HIV business, buoyed by the success of its long-acting antiretroviral therapy, Cabenuva. ...
Injectable hydrogel delivers HIV drug for six weeks in mice study
The landscape of HIV therapies has evolved significantly since the 1980s, when the FDA first approved the pioneering antiretroviral therapy ...
Patients prefer ViiV’s injectable HIV medication, according to a Switch research
When ViiV Healthcare and Johnson & Johnson introduced their once-monthly injectable HIV treatment Cabenuva in 2021, they anticipated that patients ...
Twice-Yearly Lenacapavir Boosts HIV Patients’ Quality of Life
Source – Gilead Gilead Sciences presented new data at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS ...
Biktarvy Continues to Show Safety and Efficacy Across Diverse Populations Impacted by the Global HIV Epidemic: Updated Findings from IAS 2023
Source – Gilead Gilead Sciences, has released the results of several studies further solidifying Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...
Gilead’s IAS 2023: Advancing Health Equity and HIV Pipeline Progress
Source – Gilead On July 20, a leading force in HIV innovation, announced its significant participation in the 12th International ...
To increase treatment and adherence rates for children with HIV in low- and middle-income countries, Gilead collaborates with CHAI and Penta
Source – Gilead Sciences Gilead Sciences is pleased to announce two collaborative initiatives. The first initiative aims to expedite the ...
Gilead and Teva were acquitted in a $3.6 billion trial involving alleged ‘pay-for-delay’ schemes
Gilead Sciences and Teva have been exonerated by a California court jury in a lawsuit accusing them of colluding to ...
